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2Abstract 
1,25-dihydroxyvitaminD3 (1,25(OH)2D3), has potent anti-inflammatory effects, 
including suppression of IL-17+ and IFNγ+ T cells implicated in rheumatoid arthritis 
(RA), but efficacy at the site of active disease is unclear. To investigate this, CD4+T 
cells from synovial fluid (SF) and paired blood of patients with active RA were 
studied. 1,25(OH)2D3 had significantly less suppressive effect on Th17 cells (IL-
17+IFNγ-) and Th17.1 cells (IL-17+IFNγ+) from SF compared to those from blood, 
and had no effect on SF CD4+IFNγ+ T cell frequencies. Memory T cells (CD45RO+) 
predominate in SF, and 1,25(OH)2D3 had less effect on memory T cells relative to 
naïve (CD45RA+) T cells.  RT-PCR and flow cytometry showed that this was not due 
to decreased expression of the vitamin D receptor or its transcription partners in 
memory T cells. Further studies using stimulated CD4+ T cells sorted according to 
IL-17 and IFNγ expression confirmed the ability of 1,25(OH)2D3 to suppress pre-
existing cytokines. However, 1,25(OH)2D3 was most effective at suppressing de novo 
IL-17 and IFNγ induction. Correspondingly, T cell responses to 1,25(OH)2D3 
correlated directly with capacity for phenotype change, which was lower in cells from 
SF compared to blood. These findings indicate that anti-inflammatory effects of 
1,25(OH)2D3 in active RA are impaired because of reduced effects on phenotype-
committed, inflammatory memory T cells that are enriched in SF. Restoration of 
1,25(OH)2D3 responses in memory T cells may provide a new strategy for treatment 
of inflammatory diseases such as RA.   
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31. Introduction 
The active form of vitamin D, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) promotes anti-
inflammatory responses in a diverse array of cell types, supporting the potential use 
of vitamin D in the prevention and/or treatment of inflammatory disorders [1, 2]. In 
previous studies we have shown that anti-inflammatory actions of vitamin D may 
occur indirectly through localized synthesis of 1,25(OH)2D3, and reduced expression 
of major histocompatibility and co-stimulatory molecules by antigen-presenting 
dendritic cells (DCs), monocytes and macrophages [3-6]. However, 1,25(OH)2D3 can 
also act directly on T-lymphocytes (T cells), inhibiting their  proliferation [7], 
especially under conditions of weak co-stimulation [8], and suppressing their  
production of pro-inflammatory cytokines such as IFNγ, IL-17 and IL-21 [9-13], whilst 
promoting their expression  of regulatory markers including CTLA-4, FoxP3, and IL-
10 [13] even in the presence of pro-inflammatory cytokines [14]. Crucially almost all 
of these observations have stemmed from experiments using T cells from the blood 
of healthy donors and much less is known about the effects of 1,25(OH)2D3 in 
established inflammatory disease, especially its effects upon T cells from inflamed 
compartments such as the joint of a patient with rheumatoid arthritis (RA).
Epidemiology suggests that many autoimmune diseases and common chronic 
inflammatory diseases such as RA are associated with vitamin D-deficiency [15-17]. 
Vitamin D metabolites such as 1,25(OH)2D3 may therefore provide an alternative 
strategy for the prevention and/or treatment of RA [18], possibly as an adjunct to 
existing RA therapies [8]. Previous studies have highlighted aberrant metabolism of 
vitamin D in disease-affected synovial fluid (SF) from RA patients [19], but the impact 
of 1,25(OH)2D3 on T cells from the site of inflammation, the inflamed joint, has yet to 
be studied.
4How 1,25(OH)2D3 affects T cell function is important in RA as T cells accumulate in 
the RA synovium and genetic risk factors for RA are largely related to T cell 
activation [20-25]. IFNγ+ Th1 cells and IL-17+ Th17 cells are regarded as important 
mediators of chronic synovial inflammation. Increased levels of their hallmark and 
differentiating cytokines are found in the serum and synovial fluid of patients relative 
to controls [26], and elevated frequencies of both have been detected in the blood 
and joints of RA patients [27].  IFNγ produced by Th1 cells promotes APC maturation 
whilst IL-17 has pleiotropic effects, driving fibroblast-like synoviocytes (FLS) to 
release pro-inflammatory cytokines and chemokines [28], that further amplify the 
inflammation by facilitating the recruitment and retention of immune cells, including 
CCR5+CXCR3+ Th1 cells [29, 30] and CCR6+ Th17 [31, 32] cells into the joint.  IL-
17 from Th17 cells also promotes cartilage and bone resorption by stimulating MMP 
release from FLS [28] and the induction of RANKL on FLS and osteoblasts leading to 
activation of RANK+ osteoclasts [33]. 
The aim of the current study was to investigate further the potential use of vitamin D 
as a therapy for RA, by determining whether anti-inflammatory effects of 1,25(OH)2D3 
are achievable on T cells from the site of inflammation. By comparing cells isolated 
from RA patient SF and peripheral blood we were able to demonstrate relative T cell 
insensitivity to 1,25(OH)2D3 in inflamed joints. This dysregulation of the anti-
inflammatory effects of 1,25(OH)2D3 was associated with memory (CD45RO+) T cell 
phenotype commitment. Since activated memory T cells characterize the inflamed 
tissues in multiple inflammatory diseases [34], T cell insensitivity to 1,25(OH)2D3 may 
be a feature of other inflammatory conditions and may reduce its potential 
therapeutic benefit, especially in established disease. 
52. Materials and Methods
Patients were recruited for the study if they fulfilled 1987 ACR criteria for RA [35]. All 
patients and age and gender-matched healthy controls gave full written consent. 
Ethical approval for the work was granted by Solihull Research Ethics Committee 
(REC reference number 07/Q2706/2) and the University of Birmingham Ethics 
Committee (ERN_14-0446). For naïve and memory T cell comparison studies, as 
well for as cytokine-expression cell capture experiments, cells were isolated from 
fully anonymysed leukocyte cones obtained from the National Blood Service, 
Birmingham, UK.  
2.1. Cell isolation and culture
Synovial Fluid (SF) was extracted by ultrasound guidance as described previously 
[36] or by palpation guidance. Prior to SF Mononuclear Cell (SFMC) isolation, SF 
was treated with hyaluronidase (10U/ml) for 30 minutes at 37oC. PBMCs and SFMCs 
were isolated by the Ficoll-Paque PLUS method of density gradient centrifugation 
(GE Healthcare). SF was layered on Ficoll-Paque PLUS undiluted, fresh blood was 
diluted 1:1 with PBS and leukocyte cones were diluted 1:4 with PBS before layering. 
Isolated SFMCs and PBMCs were cultured at 37oC, 5% CO2 in RPMI 1640 medium 
and supplemented with 1% penicillin and streptomycin, 2mM L-glutamine, and 5% 
self-serum or SF that was pre-filtered through a 22 µm filter. For ex vivo cytokine 
expression analysis, cells were allowed to rest overnight at 1x106 cells/ml without 
stimulation before being stimulated for 6-7 hours with phorbol myristate acetate 
(PMA) (50ng/ml) and ionomycin (1μM). Brefeldin A (10 µg/ml) was added during the 
last 4 – 5 hours. For seven-day cultures, mononuclear cells were stimulated with 
anti-CD3 (0.5μg/ml, clone OKT3) at 2.5 x 105 cells/ml.  1,25(OH)2D3 was added to 
cultures at 100 nM and ethanol used as a vehicle control at 0.1%. At seven days, 
cells were restimulated with PMA/ionomycin in the presence of brefeldin A for 
cytokine expression analysis by flow cytometry.
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For experiments using isolated CD45RA+CD4+ naïve T cells, CD45RO+CD4+ 
memory T cells and CD14+ monocytes, cells were enriched by negative selection 
using cell separation reagents (StemCell Technologies and Biolegend). For 24 hr 
post-stimulation analysis of gene expression, T cells were stimulated with anti-
CD3/CD28 dynabeads (Life Technologies) at a ratio of 1 bead: 2 T cells in medium 
supplemented with 5% human AB serum (TCS Biosciences, Buckingham UK). For 
longer-term stimulations a ratio of 1 bead: 4 T cells was used. Where T cells were 
stimulated with monocytes, a ratio of 1 monocyte: 4 T cells and OKT3 0.5μg/ml was 
used.  
2.2. Isolation and culture of Th17, Th17.1 and Th1 cells 
Expanded populations of Th17, Th17.1 and Th1 cells were generated by stimulating 
magnetically purified monocytes and CD4+ T cells at 1:5 ratio with 0.5ug/ml antiCD3 
for seven days. IL-17-PE and IFNγ-APC cytokine secretion detection kits (Miltenyi 
Biotech) were used to label live Th17, Th17.1 and Th1 cells. In brief, cultures were 
re-stimulated with Phorbol 12,13-dibutyrate (PDBu) (10ng/ml) and ionomycin (1nM) 
for 2hours before labeling with IL-17 and IFNγ catch reagents on ice at 10x106 
cells/80μl MACS buffer for 5mins. Cells were transferred to pre-warmed RPMI and 
incubated for 40mins at 37°C at 4x105 cells/ml under continual rotation. Cells were 
then diluted 1:1 with ice-cold MACS buffer and chilled on ice for 10 minutes before 
centrifuging and labelling with IL-17-PE and CD3-PerCP for 15 minutes on ice with 
addition of IFNγ-APC during the final 10 minutes. After washing, Th17, Th17.1, Th1 
and cytokine double-negative (DN) populations were collected into RPMI by FACS.  
Sorted T cells were then stimulated with negatively enriched (StemCell 
Technologies) and CD14+ FACS-purified allogenic monocytes at 1:4 ratio and 
0.5μg/ml anti-CD3 (OKT3) for 2 days in the presence of 40units/ml IL-2 
(Immunotools) ± 100nM 1,25(OH)2D3. Cell purities were >99% for Th17, Th1, DN and 
7monocytes and >90% for Th17.1 cells. 
2.3. Flow cytometry
CD45-RO+ frequencies were assessed directly ex vivo by surface staining at 4oC in 
PBS with antiCD45RO-FITC, CD3-PE and CD4-APC (all from BD Biosciences). For 
post-stimulation cultures, dead cells were labelled with near-IR LIVE/DEAD fixable 
dead cell stain (Molecular Probes, Life Technologies) before fixation. For analysis of 
regulatory markers: CTLA-4, Foxp3 and CD25, cells were fixed, permeabilised and 
stained with ebioscience/Thermofisher Foxp3 staining buffers according to the 
manufacturer’s instructions. For analysis of cytokine expression, PMA/ionomycin-
restimulated cells were fixed with 3% paraformaldehyde in PBS for 12 minutes 
followed by a 5-minute wash with PBS under centrifugation. Fixed cells were 
permeabilised with 0.1% saponin (Acros Organics) prepared in PBS and stained with 
IL-17-PE, IFNγ-e450, IL-21-APC, CD3-PERCP, CD4-FITC. For all studies cells were 
acquired on a Dako Cyan flow cytometer (Dako Cytomation) and data analysed 
using FlowJo software (Tree Star version 8.8.6). All antibodies were purchased from 
ebioscience/Thermofisher or BD Biosciences and expression quantified relative to 
the appropriate isotype control.  
2.4. Quantitative Real-time PCR
Total RNA was extracted by phenol/chloroform method after cell lysis in TRIzol (Life 
Technologies/Invitrogen). 0.3-0.5 µg RNA was reverse transcribed with random 
hexamers using TaqMan reverse transcription reagents (Thermofisher/Applied 
Biosystems). Quantitative real-time PCR for 18S rRNA, VDR, RXR, DRIP-205, 
NcOA1, NCOR1 and NCOR2, IL-17 or IFNγ was then performed on an Applied 
Biosystems 7900 machine using assays on demand from Applied Biosystems: 18S 
rRNA, (4319413E); VDR (Hs00172113_m1); RXR (Hs01067640_m1), NCoR1 
(Hs01094540_m1), NCoR2 (Hs00196955_m1), DRIP205 (Hs01062349_m1), NCoA1 
8(Hs00186661_m1); IL-17 (Hs99999082_m1) and IFNγ(HS00989291_m1). 
Amplification of cDNAs involved incubation at 50°C for 2 minutes and 95°C for 10 
minutes followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. VDR 
mRNA expression was then calculated relative to 18S rRNA using the delta Ct 
method as described previously [37]. 
2.5. Statistical analysis
GraphPad Prism 5.0a software (GraphPad) was used for graphical summary and 
statistical analysis. For analysis of normality and Q-Q plot inspection SPSS statistics 
version 22 was used. Non-parametric Wilcoxon tests were used to test significance 
between two conditions. To test interactions between 1,25(OH)2D3 and cell source 
location repeated measures two factor within subject analysis with Huynf-Feldt 
correction was performed. The Shapiro-Wilk normality test and inspection of normal 
Q-Q plots were used to confirm that the data could be tested with these parametric 
models. For data sets that did not pass the normality test (VDR mRNA) the data 
were log10 transformed, since by this transformation the residuals from the mean 
became normally distributed.
3. Results
3.1. Anti-inflammatory effects of 1,25(OH)2D3 are reduced in synovial fluid T 
cells
To determine whether T cells from patients with active RA are sensitive to the anti-
inflammatory effects of 1,25(OH)2D3, peripheral blood mononuclear cells (PBMCs) 
from the blood of healthy controls and established RA patients, as well as synovial 
fluid (SF) mononuclear cells (SFMCs) from RA patients, were stimulated with anti-
CD3 in the presence or absence of 1,25(OH)2D3 for seven days and the frequency of 
CD4+ T cells expressing IL-17 or IFNγ measured by flow cytometry (Figure 1A and 
1B). 1,25(OH)2D3 decreased IL-17+ and IFNγ+ T cell frequencies in HC and RA 
9PBMCs. It also reduced frequencies of IL-17+ T cells in SFMC cultures. However 
1,25(OH)2D3 had no effect on the frequency of IFNγ+ T cells in SFMCs (Figure 1B). 
Further classifying T cells according to their combined expression of IL-17 and IFNγ 
revealed significantly greater suppressive effects of 1,25(OH)2D3 on Th17 (IL-
17+IFNγ-) and Th17.1 (IL-17+IFNγ+) T cells in RA blood relative to SF, whilst Th1 
(IL-17-IFNγ+) frequencies were not affected by 1,25(OH)2D3 in blood or SF (Figure 
1C). Thus Th17 and Th17.1 populations from the inflamed joints of RA patients are 
less sensitive to the anti-inflammatory effects of 1,25(OH)2D3 than equivalent 
circulating T cells.  
3.2. Effects of 1,25(OH)2D3 are greater on blood naïve versus memory T cells 
Consistent with previous studies [38], only 47% (± 12%) T cells isolated from blood 
were memory (CD45RO+). By contrast, 98% (± 2%) SF T cells were CD45RO+ 
(Supplemental Figure 1). We therefore determined whether the decreased effect of 
1,25(OH)2D3 upon SF T cells could be attributed to differences between memory and 
naïve T cells. As shown in Figure 2A, IL-17+ and IFNγ+ T cells were more abundant 
in memory T cell populations. Treatment with 1,25(OH)2D3 suppressed IFNγ+ and IL-
17+ frequencies in both naïve and memory subsets.  For IL-17, 1,25(OH)2D3 had 
equal effect on naïve and memory T cells whereas the effect of 1,25(OH)2D3 on IFNγ 
expression was greatest for naïve T cells (Figure 2B). 1,25(OH)2D3 also had greatest 
effect upon IL-21 and CTLA-4 expression in naïve T cells compared to memory T 
cells, with 1,25(OH)2D3 inducing CTLA4 in naïve T cells but having no effect on 
memory T cells (Figure 2A and 2B).  
As it is unclear how many rounds of stimulation circulating memory T cells have 
experienced in vivo, we also compared the effect of 1,25(OH)2D3 on naïve and 
memory T cells during sequential rounds of stimulation (Supplemental Figure 2). 
Analysis of three cytokines (IL-17, IFNγ, and IL-21) showed that 1,25(OH)2D3 was 
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more effective in naïve versus memory T cells at the first round of stimulation, but 
this difference in sensitivity was lost following the second round of T cell stimulation. 
These data support the concept that induction of a memory T cell phenotype reduces 
the anti-inflammatory effects of 1,25(OH)2D3 on T cells, which may in part explain the 
differences in 1,25(OH)2D3 responses between blood and SF T cells. 
3.3. 1,25(OH)2D3 signaling components in naïve versus memory T cells 
To investigate the underlying basis for reduced 1,25(OH)2D3 responsiveness in 
memory versus naïve T cells, expression of the nuclear vitamin D receptor (VDR), its 
retinoid X receptor (RXR) heterodimer partner, as well as associated 
activator/repressor proteins was assessed. RT-PCR analyses and flow cytometry 
showed similar low levels of VDR in unstimulated naïve and memory T cells, with 
VDR expression increasing in both T cell populations following stimulation (p<0.05 
for mRNA and protein in stimulated naïve and memory T cells versus unstimulated 
naïve and memory T cells) (Figure 3A). Similar to VDR, unstimulated naïve and 
memory T cells showed comparable low expression of RXR, but only memory T cells 
showed induction of this receptor upon stimulation (Figure 3B). In addition to VDR 
and RXR, several co-regulators participate in 1,25(OH)2D3-mediated transcriptional 
responses, and these factors may contribute to variable responses to 1,25(OH)2D3 
[39]. However, analysis of mRNAs for the co-enhancers DRIP205 and NcOA1, and 
co-repressors NcoR1 and NcoR2, showed no difference in expression between 
naïve and memory T cells (Figure 3C). The decreased 1,25(OH)2D3 responsiveness 
of memory versus naïve T cells could therefore not be attributed to impaired 
expression of VDR or its signaling partners. 
  
3.4. Effects of 1,25(OH)2D3 in SF versus blood memory T cells
To determine whether decreased responses to 1,25(OH)2D3 in SF compared to blood 
T cells involve differences between memory T cells from the two compartments, 
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matched CD45RO+ CD4+ memory T cells from paired blood and SF of RA patients 
were stimulated in the presence or absence of 1,25(OH)2D3. Flow cytometry for IFNγ 
and IL-21 showed decreased anti-inflammatory effects of 1,25(OH)2D3 in SF versus 
blood memory T cells, whilst a non-significant trend was observed for IL-17 (Figure 
4A). Flow cytometry and RT-PCR revealed enhanced VDR expression in 
unstimulated memory T cells isolated from SF relative to those obtained from blood 
(Figure 4B and 4C), consistent with their more activated (CD69+) phenotype 
(Figure 4C). VDR expression increased following memory T cell stimulation (p<0.001 
for stimulated versus unstimulated cells), but there was no significant difference in 
VDR expression between stimulated blood and stimulated SF cells (Figure 4B). By 
contrast, mRNA for RXR did not differ in blood versus SF memory T cells in the 
stimulated or unstimulated state (Figure 4B). The co-regulators DRIP205, NcoA1, 
NcoR1 and NcoR2 also showed elevated expression in unstimulated memory SF T 
cells (Supplemental Figure 3), similar to that observed for VDR. Collectively these 
data indicate that SF memory T cells are less affected by 1,25(OH)2D3 than memory 
T cells from blood, but this is not due to impaired expression of VDR or its signaling 
partners. 
3.5. Effects of 1,25(OH)2D3 on Th17, Th17.1 and Th1 cells 
To date, reported anti-inflammatory effects of 1,25(OH)2D3 have been based on data 
from mixed cultures of cytokine-expressing and non-expressing T cells. Further 
studies were therefore carried out to determine the effects of 1,25(OH)2D3 on T cells 
expressing specific cytokines. By combining anti-IL-17-PE and anti-IFNy-APC 
cytokine detection reagents, live T cells were labeled according to their expression of 
IL-17 and/or IFNγ, and Th17, Th17.1, Th1 cells were obtained by FACS as well as T 
cells double negative for IL-17 and IFNγ (DN). RT-PCR analysis of IL-17 and IFNγ 
mRNA in the sorted populations confirmed cytokine purity of the sorted cells 
(Supplemental Figure 4). The Th17, Th17.1 and Th1 T cells generated in this 
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manner were then re-stimulated in the presence or absence of 1,25(OH)2D3 for two 
days. In vehicle-treated re-stimulated populations, we observed plasticity of 
phenotype between Th17, Th17.1 and Th1, including the generation of T cells double 
negative for IL-17 and IFNγ (Figure 5A). Th17 cells could give rise to IFNγ-
expressing T cells, and Th1 cells could induce IL-17expression. DN cells could also 
give rise to IL-17 and IFNγ (Figure 5A). 
Treatment with 1,25(OH)2D3 reduced expression of IL-17 or IFNγ in T cells pre-
committed to Th17 and Th1 phenotypes respectively, but 1,25(OH)2D3 had a much 
greater inhibitory effect on de novo expression of IL-17 or IFNγ (Figure 5A & Figure 
5B). In Th17 cells, 1,25(OH)2D3-sensitivity was greater for IFNγ than IL-17, whilst the 
opposite response was observed in Th1 cells. Moreover, 1,25(OH)2D3 actively 
suppressed the development of Th17, Th17.1 and Th1 populations from DN T cells, 
but had little effect on IL-17 or IFNγ expression in Th17.1 T cells that had pre-existing 
expression of both IL-17 and IFNγ (Figure 5B). 
3.6. Capacity for phenotype change is low in SF T cells 
Further studies were carried out to determine if the impaired response to 
1,25(OH)2D3 observed for SF versus blood T cells was due to differences in T cell 
phenotype commitment and plasticity. This was carried out by comparing the 
cytokine profiles of blood and SF T cells ex vivo and after stimulation. There were 
few IL-17+ T cells in blood ex vivo and these were almost exclusively Th17 (Figure 
6A, 6B and 6D). IL-17 expression was also low in SF, but this was evenly distributed 
across Th17 and Th17.1 populations (Figure 6D). Compared to IL-17, considerably 
more T cells expressed IFNγ ex vivo in blood and SF, however, the frequency of 
IFNγ+ cells was much higher in SF compared to paired blood. Culture of T cells from 
blood for 7 days resulted in significant expansion of IL-17+ T cells (12-fold) (Figure 
6C), with the Th17.1 population showing greatest fold change (50-fold) (Figure 6D). 
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IFNγ+ Th1 cells from blood showed no change in frequency from ex vivo to 7 days of 
culture (Figure 6A and 6D). In contrast to blood, culture of T cells from SF resulted 
in only a 2-fold induction of Th17 T cells and a 4-fold induction of Th17.1 T cells, with 
Th1 cells (the largest fraction of IFNγ+ T cells in SF), again showing no change in 
frequency from ex vivo to 7 days of culture (Figure 6D).
The capacity for expansion of IL-17+ T cells during culture correlated directly with the 
ability of these cells to respond to 1,25(OH)2D3, with Th17 and Th17.1 cells from 
blood being more effectively suppressed by 1,25(OH)2D3 than their SF counterparts 
(Figure 7). By contrast, the lack of phenotype plasticity shown for Th1 cells and cells 
from SF (Figure 6A-D), was associated with lower sensitivity to 1,25(OH)2D3 (Figure 
7). The lack of an anti-inflammatory response to 1,25(OH)2D3 in SF T cells therefore 
appears to be due to the limited phenotype plasticity exhibited by these cells. 
4. Discussion 
Vitamin D metabolites such as pro-hormone 25-hydroxyvitamin D (25OHD) and 
active 1,25(OH)2D3 are detectable in SF from RA patients [19, 40], and monocytes 
isolated from SF have been shown to actively synthesize 1,25(OH)2D3 from 25OHD 
[19, 41]. Thus, there is significant potential for elevated concentrations of 
1,25(OH)2D3 within inflamed joints. In addition, VDR is broadly expressed and 
present within cells from synovial tissue and fluid [42] indicating that different 
components of the inflamed joint have the capacity to respond to 1,25(OH)2D3, in an 
intracrine or paracrine fashion [18].  As recently summarized [18], multiple in vitro 
studies also demonstrate anti-inflammatory effects of 1,25(OH)2D3 upon the immune 
cells that contribute to RA pathology. However, these studies have focused on cells 
from the blood of healthy controls or RA patients. The extent to which anti-
inflammatory responses to 1.25(OH)2D3 also occur in immune cells from inflamed 
tissue is still poorly understood, but is nevertheless crucially important when 
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considering the potential use of 1,25(OH)2D3 as a therapy for inflammatory diseases.  
Th1 and Th17 cells are believed to contribute to inflammatory conditions such as RA 
[43], and are both recognized inhibitory targets for 1,25(OH)2D3. Vitamin D 
supplementation may prevent, slow or reverse inflammatory disease by inhibiting 
these T cell subsets. The current study addressed the question of 1,25(OH)2D3 
responsiveness in cells from inflamed tissues by comparing effects of 1,25(OH)2D3 
on IL-17 and IFNγ+ expression by CD4+ T cells derived from matched blood and SF 
samples from RA patients. Whilst 1,25(OH)2D3 strongly inhibited both IL-17+ and 
IFNγ+ frequencies in cells from blood, there was no significant effect on IFNγ 
frequencies in cells from SF, suggesting a loss of 1,25(OH)2D3 sensitivity in T cells 
from the inflamed site. 
Both naïve (CD45RA+) and memory (CD45RO+) T cells were able to respond to 
1,25(OH)2D3, but inhibition of inflammatory cytokines was more pronounced for naïve 
T cells, and became less effective upon transition from naïve to memory. These 
findings suggest that variations in the proportion of naïve to memory T cells play a 
key role in defining the anti-inflammatory impact of 1,25(OH)2D3 in vivo, especially at 
the inflammatory site where memory T cells are the dominant T cell type [38]. 
Furthermore, whilst naïve to memory transition accounted for most of the loss in 
1,25(OH)2D3 effect upon SF T cells, comparing memory T cells from blood with those 
from SF revealed a further decline in 1,25(OH)2D3 sensitivity in SF cells. Collectively, 
these data indicate that analysis of 1,25(OH)2D3-responses using T cells from blood, 
even blood from RA patients, may over-estimate the ability of vitamin D to regulate 
inflammatory T cells in disease-affected synovial fluid. 
Th17 and Th1 T cell subsets not only play a critical role in the pathophysiology of 
inflammatory diseases such as RA, they are also pivotal to host responses to 
infectious pathogens such as Mycobacterium tuberculosis [44]. In this setting, 
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1,25(OH)2D3 is proposed to be less effective in the early stages of infection, where T 
cells are not chronically activated and therefore have lower levels of VDR 
expression. The resulting insensitivity to 1,25(OH)2D3 during early infection is 
advantageous in enabling maintenance of inflammatory T cell populations for 
maximal clearing of pathogenic antigen [45]. By contrast, at later stages of immune 
response to infection, more activated T cells express higher levels of VDR and are 
therefore more sensitive to 1,25(OH)2D3, with the principal response being 
minimization of T cell activity and chronic inflammation [45]. Data from the current 
study suggest that in chronically activated T cells from inflammatory sites such as the 
rheumatoid joint, there is re-instigation of 1,25(OH)2D3-insensitivity. However, in 
contrast to early stage T cell responses, decreased responsiveness to 1,25(OH)2D3 
in activated SF T cells does not appear to be due to lower VDR-binding capacity for 
1,25(OH)2D3:  VDR expression was increased in SF T cells ex vivo consistent with 
the activated CD69+ phenotype of these cells, and levels of VDR and co-regulator 
proteins were similar for blood and SF T cells following in vitro stimulation. Likewise 
differential expression of VDR and its co-regulators did not account for the lesser 
effect of 1,25(OH)2D3 on anti-inflammatory responses by memory vs naïve T cells. 
An additional feature of memory T cells versus naïve is their commitment to 
phenotype as defined by cytokine expression. T cells that express multiple 
inflammatory cytokines including those doubly expressing IL-17 and IFNγ (Th17.1 
cells) are regarded the most pathogenic in inflammatory disease [46]. 
Correspondingly, Th17.1 cells were present at increased frequency in SF T cells ex 
vivo compared to blood. Previous studies into 1,25(OH)2D3 effects upon T cell 
cytokine expression have used mixed cultures of cytokine-expressing and non-
expressing cells, making it impossible to determine effects of 1,25(OH)2D3 upon 
phenotype-committed T cells which, as our data on phenotype maintenance following 
stimulation suggest, are more enriched in SF compared to blood.  By using novel 
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cytokine cell capture methods to sort live Th17, Th17.1, Th1 and double negative 
cells into separate populations, the current study showed that responses to 
1,25(OH)2D3 are in fact highly dependent on the commitment of T cells to a particular 
phenotype: 1,25(OH)2D3 treatment strongly suppressed conversion of cytokine naïve 
T cells into inflammatory effector cells as well as the transition of one effector 
phenotype to another through induction of a new cytokine. By contrast, 1,25(OH)2D3 
was much less efficient at suppressing an existing T cell phenotype. T cells from SF 
displayed a more committed phenotype relative to blood as indicated by only small 
increases in Th17 and Th17.1 and no change in Th1 frequency following stimulation. 
Thus, whilst 1,25(OH)2D3 reduced expression of IL-17 and IFNγ in less phenotype-
committed blood T cells by preventing new cytokine gene expression, it was much 
less effective as an inhibitor of established cytokine gene expression in SF T cells. 
An important conclusion from these studies is that terminal commitment of memory T 
cells to a specific phenotype, as prevalent in disease-affected tissues such as RA 
synovium, plays a central role in attenuating anti-inflammatory effects of 
1,25(OH)2D3. In concert with 1,25(OH)2D3, VDR functions as a transcription factor to 
regulate expression of genes such as IL-17 and IFNγ that have functional vitamin D 
response elements (VDRE) [47, 48]. This process is subject to genomic variation, but 
is also strongly influenced by epigenetic mechanisms that may lead to intra-individual 
[49], or disease-specific [39] changes in 1,25(OH)2D3-VDR signaling. Recent studies 
have shown that memory T cell development is associated with specific epigenetic 
signatures that strongly influence transcriptional regulators [50]. Thus, it seems likely 
that variations in response to 1,25(OH)2D3 according to naïve and memory state and 
extent of phenotype commitment will be due to epigenetic modifications that could 
strongly influence chromatin remodeling, and VDRE accessibility. In future studies it 
will be interesting to investigate the potential use of epigenetic modulators in 
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correcting the 1,25(OH)2D3-insensitivity characteristic of T cells from RA disease-
associated tissue.  
5. Conclusion 
Data in the current study endorse the potential use of vitamin D and/or 1,25(OH)2D3 
in controlling the de novo generation of Th17 and Th17.1 cells that are associated 
with inflammatory disease. However, the limited effect of 1,25(OH)2D3 on phenotype-
committed T cells from the site of inflammation suggests that vitamin D 
supplementation is unlikely to be successful as treatment for established active RA 
patients. Consistent with this hypothesis, not all early vitamin D supplementation 
trials in RA have reported positive effects of the treatment [51-53]. The fact that 
peripheral blood T cells from patients were responsive to the anti-inflammatory 
effects of 1,25(OH)2D3, and equally as responsive as those from healthy donors, 
nevertheless supports a use for vitamin D in the management of RA, either as a 
prophylactic or to reduce the risk of future disease flares in patients in remission. 
Owing to its powerful anti-inflammatory effects in vitro, vitamin D supplementation 
has been proposed as a cost-efficient, ‘natural’ and low-risk treatment strategy in 
multiple inflammatory diseases. However, since memory T cells with committed 
inflammatory phenotypes dominate the inflamed tissues in multiple inflammatory 
conditions, this study raises questions about widespread application of vitamin D 
therapy in the management of inflammatory diseases, especially cases of 
established, active disease. Further studies are required to identify the cause of the 
insensitivity to 1,25(OH)2D3 at the molecular level. Strategies to overcome this and 
restore 1,25(OH)2D3 sensitivity  in inflammatory phenotype-committed memory T 
cells at the inflamed site may provide a novel approach to the treatment of RA and 
other inflammatory diseases.
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Figure Legends
Figure 1. Anti-inflammatory effects of 1,25(OH)2D3 are reduced in T cells from 
synovial fluid compared to peripheral blood. Mononuclear cells from the 
peripheral blood of healthy controls (HC) and the blood and synovial fluid (SF) of RA 
patients were stimulated with anti-CD3 for seven days in the presence or absence of 
1,25(OH)2D3 (+1,25D) and frequencies of IL-17+ and IFNγ+ CD4+ T cells quantified 
by flow cytometry (A). Representative bivariate plots of IL-17 versus IFNγ expression 
by CD4+ T cells showing IL-17+/IFNγ- (Th17), IL-17+IFNγ+ (Th17.1) and IL-17-
IFNγ+ (Th1) subsets for cells from RA blood vs RA SF. (B). Significant effects of 
1,25(OH)2D3 were tested for HC (n=9), RA blood (n=12), RA SF (n= 11) by Wilcoxon 
matched pairs or Mann Whitney nonparametric tests as appropriate (C). Effect of 
1,25(OH)2D3 on Th17, Th17.1 and Th1 populations quantified by frequency in 
respective gate under untreated/1,25D conditions. Significance was tested by 
repeated measures two-way ANOVA.  ns= non-significant, * = P<0.05, **=P<0.01, 
***=P<0.001.
Figure 2: Effects of 1,25(OH)2D3 are greater on naïve than memory T cells. Naive 
and memory CD4+ T cells were purified from the peripheral blood of healthy controls 
and stimulated with autologous monocytes and anti-CD3 in the presence or absence 
of 1,25(OH)2D3 (+1,25D). Frequency of cells expressing IL-17, IFNγ and IL-21 was 
quantified at seven days and expression of CTLA-4 and FoxP3 measured at four 
days by flow cytometry. (A) Representative FACS plots for one donor are shown 
(left), and frequencies of cytokine positive cells and CTLA-4 median fluorescence 
intensity (MFI) summarised as dot plots for n=6 donors for vehicle (closed symbols) 
and 1,25(OH)2D3 (+1,25D)-treated cells (open symbols) (right). (B) The effect of 
1,25(OH)2D3 on IL-17, IFNγ and IL-21 was compared for naïve and memory T cells 
by frequency of positive cells under untreated/1,25D conditions. A lower frequency 
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limit of 0.001% was used for these calculations. 1,25(OH)2D3 effect on CTLA-4 was 
estimated by MFI under 1,25D/untreated conditions. Significant differences were 
tested using Wilcoxon matched pairs tests. ns= non-significant, * = P<0.05, 
**=P<0.01, ***=P<0.001.
Figure 3: Memory and naïve T cells express similar levels of vitamin D 
response machinery. RNA was purified from naive and memory CD4+ T cells from 
the peripheral blood of healthy controls before and after stimulation with 
antiCD3/CD28 beads. Regulators of response to 1,25(OH)2D3 including (A) Vitamin 
D receptor (VDR), (B) Retinoid X Receptor (RXR), (C) VDR co-regulators: DRIP205, 
NcoA1, NcoR1 and NcoR2 were measured by qPCR. mRNA expression for each 
gene is shown relative to matched memory T cells. VDR protein in T cells was also 
measured by flow cytometry before and after stimulation with PMA and ionomycin. 
Stimulated T cells were defined as CD69+.  Statistical significance was tested by 
repeated measures two-way ANOVA.  * = P<0.05, **=P<0.01.
Figure 4. Memory T cells from synovial fluid are relatively insensitive to 
1,25(OH)2D3 compared to memory T cells from peripheral blood. CD45-RO+ 
memory T cells were isolated from synovial fluid (SF) and peripheral blood of 
established RA patients and stimulated with anti-CD3/CD28 beads in the presence or 
absence of 1,25(OH)2D3 (+1,25D) overnight or for 5 days. Response to 1,25(OH)2D3 
was assessed by measurement of IL-17, IFNγ and IL-21 by flow cytometry at 5 days 
and relative expression of cytokines in the presence vs the absence of 1,25(OH)2D3 
calculated for n>9 donors (A). Significant differences were tested using Wilcoxon 
matched pairs tests. ns= non-significant, * = P<0.05. (B) Effects of cell location and 
20hr stimulation on VDR and RXR mRNA transcripts were examined by qPCR (B). 
Expression is given relative to the level in unstimulated memory cells. Statistical 
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significance was tested by repeated measures two-way ANOVA. * = P<0.05, 
***=P<0.001, ns = not significant. VDR expression in CD4+ T cells from blood and 
synovial fluid was also assessed by flow cytometry for n=3 donors. Representative 
data for CD69 versus VDR are shown in (C).
Figure 5. 1,25(OH)2D3 suppresses cytokine expression by pre-committed Th17, 
Th17.1 and Th1 cells but most potently affects novel phenotype induction
CD4+ T cells from healthy control blood were stimulated with monocytes and anti-
CD3 for seven days and sorted into IL-17+IFNγ- (Th17), IL-17+IFNγ+ (Th17.1), IL-
17-IFNγ+ (Th1) or double negative (DN) subsets using cytokine secretion assays and 
flow cytometry. After two day culture with monocytes and anti-CD3 in the presence or 
absence of 1,25(OH)2D3 (+1,25D) T cells were re-analysed for IL-17 and IFNγ 
expression by flow cytometry. (A) Data from one donor, representative of three 
studied. (B) Effect of 1,25(OH)2D3 upon total IL-17 and total IFNγ expression by 
sorted subsets, calculated as the ratio of cells expressing the cytokine under 
untreated vs treated conditions. 
Figure 6.  Capacity for phenotype change upon stimulation is reduced in SF T 
cells. IL-17 and IFNγ expression by CD4+ T cells from the peripheral blood and 
synovial fluid of RA patients was measured by flow cytometry ex vivo and after anti-
CD3 stimulation for seven days. (A) Representative bidirectional FACS plots of IL-17 
versus IFNγ in T cells from blood and synovial fluid (SF) from a single RA donor ex 
vivo and after 7 days of culture. (B) Summary of T cell frequencies in blood and 
synovial fluid (SF) for multiple donors ex vivo and after 7 days of culture. Significant 
differences were tested using Wilcoxon matched pairs tests. * = P<0.05, **=P<0.01, 
***=P<0.001. (C) XY plots for frequencies of IL-17+ and IFNγ+ CD4+ T cells ex vivo 
and after seven days. Diagonal lines indicate equal frequencies at each time point. 
(D) Pie charts summarizing the frequencies of Th17 (pale grey), Th17.1 (dark grey), 
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Th1  (black) and double negative (DN) (white) CD4+ T cells from blood and SF ex 
vivo and after 7 days of culture (n=12 donors).
Figure 7. T cell responses to 1,25(OH)2D3 correlate directly with capacity for 
phenotype change. Bidirectional plot of fold change in frequency of the population 
(Th17 blood (Bld), Th17 synovial fluid (SF), Th17.1 Bld, Th17.1 SF, Th1 Bld, Th1 SF) 
after seven day culture under control conditions versus the ratio of the population 
frequency in the presence versus the absence of 1,25(OH)2D3. Correlation 
significance was tested by Pearson’s analysis and the linear regression line with 95% 
confidence interval (hashed line) is shown.  
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